Profile picture
Erin McCreary @ErinMcCreary
, 23 tweets, 27 min read Read on Twitter
Round 2 of the Great ID Debates of #ASHP18 @ASHPOfficial comes to us from the brilliant minds of @SIDPharm members @TimbrookTT and @julie_justo. To start us off, Tristan makes the case for #fidaxomicin (FID) for treatment of Clostridioides difficile (#cdiff) infection
.@TimbrookTT sets up the major points for FID in the treatment of #Cdiff: 1- ⬇️recurrence compared to #vancomycin (VAN) in RCTs + ⬆️in cure without recurrence (aka global clinical cure) 2- this held up in real-world data 3- cost-effectiveness analyses support 1st line use #ASHP18
.@TimbrookTT notes the 2018 @IDSAInfo guidelines for #cdiff (…) recommend FID equally to VAN and for first recurrence, quality of evidence is higher 👀🤔#ASHP18
.@TimbrookTT reviews 2011 RCT of FID v VAN for initial #cdiff episode ( ➡️FID noninferior to VAN for clinical cure & associated w/ significantly lower rates of recurrence. No difference for NAP1/BI/027 strains but be careful with subgroup analysis #ASHP18
More phase 3⃣data shared by @TimbrookTT (meanwhile, on stage, @julie_justo is calm, cool, and collected). Here, FID shows ⬆️clinical cure among patients on concomitant antibiotics and ⬇️recurrence among patients with cancer #ASHP18
.@TimbrookTT reminds audience of great point: "Whenever you’re evaluating literature, think about plausibility of authors conclusions. Is it plausibile that FID would have ⬇️ recurrence compared to VAN?" Dr. Timbrook thinks, yes. #ASHP18
.@TimbrookTT continues to make the case for FID in the treatment of #cdiff by citing real-world clinical data as well as recent data from @ESCMID Congress 2018 showing VAN-treated patients were more likely to develop #VRE than patients treated with other therapies #ASHP18
The #fidaxomicin side closes out w/cost-effectiveness data, including this study from @SIDPharm member @JGPharmD showing cost savings of $3,047 per patient treated w/FID ( @TimbrookTT closing argument: "so FID is kind of awesome, I guess" #ASHP18
NEXT UP! @julie_justo takes the stage to make the case for #vancomycin (VAN) in the treatment of #cdiff. Her main points: 1- VAN is the gold standard ⭐️2- patient accessibility to VAN >>> FID 3- differences in recurrence rates can be mitigated by other factors #ASHP18
.@julie_justo also highlights the new #cdiff guidelines, noting VAN is the recommended treatment for all definitions of #cdiff. FID seems to be missing from some of these categories. whatcha think, @TimbrookTT 🤔 #ASHP18
and @julie_justo reminds us not to mess with success. VAN has shown superiority over other therapies, but no studies show FID superiority over VAN.
Justo: "RIP tolevamer, we really appreciate the comparator data you gave us” #ASHP18
.@julie_justo to the audience: "I'm not hiding data from you!" There are no differences in clinical cure, yet VAN is associated w/ ⬇️sustained response compared to FID. However, there's a lot more to consider why this is the case. #ASHP18
And let's be real... VAN plays well with others. It is accessible, available, comes in capsules and liquid, and affordable for most patients. Check out that price comparison... woof. #ASHP18 @julie_justo
.@julie_justo asks, can we really use FID first-line in everyone? Realistically, no. The. Struggle. Is. Real. Have you ever tried to get this drug approved for your patient? Absolute nightmare. #ASHP18
As for the recurrence data favoring FID... it is compared to VAN x 10 days. What about extended courses, taper, and/or pulse regimens of VAN to ⬇️recurrence? @julie_justo "I can’t remember the last time I gave a patient only 10 days of vancomycin” #ASHP18
This study found for early fecal microbiota transplant (FMT) a NNT to save 1 life @ 3 months in severe CDI cases of TWO! #ASHP18 @julie_justo "If that’s not impressive, I don’t know what is. 1 retro study so biases for sure, but still compelling data."
Can you give a #cdiff talk & not mention #kefir? @julie_justo making #twitterless Kevin Garey proud discussing this 🍓wonder. Not perfect data, but interesting for sure. This is a potential counseling point for our pts. help diversify & reconstitute a healthy microbiome! #ASHP18
.@julie_justo closes out the debate (and really, the FID > for recurrence argument) by stating: "let's be real... just give me the 💩, please." FMT data promising and our patients have other options aside from exceedingly expensive FID #ASHP18
.@TimbrookTT with the rebuttal. The "FID for everyone" concern would be less of an issue if we improved #cdiff testing #ASHP18
.@TimbrookTT also points out that risk scores, while helpful, are not a panacea. All risk scores need validated at local institutions. Lots of heterogeneity. #ASHP18
And with his final slide.... @TimbrookTT asks @julie_justo if she would treat her beloved colleague, fellow @sidpharm and @accpinfdprn member Dr. @BBookstaver_USC, with VAN over FID? Justo quickly replies-- she sure would. #ASHP18
.@julie_justo rebuttal and closing arguments include incremental cost-effectiveness ratio data and real-world fidaxomicin use data with mixed results, noting it is difficult to predict the impact of expanding FID use at your institution #ASHP18
This marks the end of the debate. Audience poll = 💯in favor of vancomycin, however EXCELLENT discussion on both sides. Amazing job @TimbrookTT @julie_justo and if you missed it, check out this debate from @BWDionne and @PharmerMeg as well:
Missing some Tweet in this thread?
You can try to force a refresh.

Like this thread? Get email updates or save it to PDF!

Subscribe to Erin McCreary
Profile picture

Get real-time email alerts when new unrolls are available from this author!

This content may be removed anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member and get exclusive features!

Premium member ($30.00/year)

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!